Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation

被引：0
作者：
Zhu Zhu
Zhu Shen
Aiming Shi
Cunjin Su
Jiaojiao Mao
Hong Tao
Feng Xu
Zhanhong Hu
Jie Pan
机构：
[1] The Second Affiliated Hospital of Soochow University,Department of Pharmacy
来源：
Heart and Vessels | 2022年 / 37卷
关键词：
Dabigatran etexilate; Dabigatran; Plasma concentration; Non-valvular atrial fibrillation; Clinical outcome;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
This study aimed to evaluate the variability of dabigatran plasma concentration and the association with clinical events in Chinese patients treated with dabigatran etexilate (DE) for non-valvular atrial fibrillation (NVAF). The steady-state concentration of dabigatran (the active metabolite of DE) was determined at trough and peak. The effect of dabigatran concentration variability and related factors on clinical outcomes were explored. Data from 86 patients receiving a fixed dose of 110 mg showed that dabigatran trough concentration varied remarkably. Age, BMI and history of heart failure were identified as important covariates for dabigatran trough concentration. Dabigatran trough concentration (P = 0.002) and history of hypertension (P = 0.012) scores were identified as key factors for predicting the risk of bleeding events. Dabigatran trough concentration, affected by Age, BMI and history of heart failure, may serve as an independent risk factor for bleeding events in Chinese patients treated with DE for NVAF.
引用
收藏
页码：821 / 827
页数：6
相关论文
共 179 条
  • [1] Chan N(2020)Direct oral anticoagulants: evidence and unresolved issues Lancet 396 1767-1776
  • [2] Sobieraj-Teague M(2009)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139-1151
  • [3] Eikelboom JW(2014)The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) J Am Coll Cardiol 63 321-328
  • [4] Connolly SJ(2015)Dabigatran concentration: variability and potential bleeding prediction in "real-life" patients with atrial fibrillation Basic Clin Pharmacol Toxicol 117 323-329
  • [5] Ezekowitz MD(2016)Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation Thromb Res 145 100-106
  • [6] Yusuf S(2019)Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants J Thromb Haemost 17 1064-1072
  • [7] Eikelboom J(2018)Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants J Thromb Haemost 16 842-848
  • [8] Oldgren J(2016)Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics Thromb Res 137 178-183
  • [9] Parekh A(2013)Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation Stroke 44 1891-1896
  • [10] Pogue J(2019)Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation J Formos Med Assoc 118 1154-1160
12345678910